RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitati...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerchel, I S, Hoogkamer, A Q, Ariës, I M, Steeghs, E M P, Boer, J M, Besselink, N J M, Boeree, A, van de Ven, C, de Groot-Kruseman, H A, de Haas, V, Horstmann, M A, Escherich, G, Zwaan, C M, Cuppen, E, Koudijs, M J, Pieters, R, den Boer, M L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886052/
https://www.ncbi.nlm.nih.gov/pubmed/28972594
http://dx.doi.org/10.1038/leu.2017.303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886052/
https://www.ncbi.nlm.nih.gov/pubmed/28972594
http://dx.doi.org/10.1038/leu.2017.303

Ejemplares similares